Under construction – not a live service
Sign in
Taking people in AustraliaPhase 1

Study of BHV-1300 in Graves' Disease

Key facts

Where
Fitzroy, Herston, Kotara, Melbourne, Oaklands Park, Parkville, St Leonards, and Torquay, AustraliaSee the 8 sites
Phase
Phase 1

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Source: NCT06980649, who can take part

Where in Australia

  • FitzroyHospital not named in the registryContact: Chief Medical OfficerTaking people
  • HerstonHospital not named in the registryContact: Chief Medical OfficerTaking people
  • KotaraHospital not named in the registryContact: Chief Medical OfficerTaking people
  • MelbourneHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Oaklands ParkHospital not named in the registryContact: Chief Medical OfficerTaking people
  • ParkvilleHospital not named in the registryContact: Chief Medical OfficerTaking people
  • St LeonardsHospital not named in the registryContact: Chief Medical OfficerTaking people
  • TorquayHospital not named in the registryContact: Chief Medical OfficerTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Biohaven Therapeutics Ltd.
Trial code
NCT06980649
Record updated
31 July 2026
Original description
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.Read full original descriptionShow less

An Open-Label Biomarker Study of BHV-1300 in Graves' Disease

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Inclusion: Participants must have serologically confirmed Graves' Disease.

Exclusion: History of treatment with radioactive iodine or thyroid surgery; History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.

ClinicalTrials.gov NCT06980649